Rich Gliklich: As there is more intent to integrate evidence across the full drug development continuum, are you seeing more alignment with your client organizations in terms of their real-world development strategies?

21 Jun 2023

Written by The Evidence Base

Artificial intelligence and machine learning Comparative effectiveness research Decision science Health data Health economics Health equity Health policy Health technology assessment Methodology Outcomes research Patient engagement Real-world evidence Regulation Stakeholder engagement Trial methodologies Value assessment

In this ‘Patti’s People’ video series, Patti Peeples of the The Peeples Collaborative speaks with Rich Gliklich (CEO, OM1) about alignment of real-world development strategies to integrate evidence across the full drug development continuum. Rich Gliklich CEO OM1, Inc. Dr Richard Gliklich is the CEO of OM1, a data and technology company focused on real-world data and artificial intelligence (AI) to support medical research, outcomes measurement and personalized medicine. Previously, he was founder and CEO of Outcome, which he led from inception through its acquisition by Quintiles (IQVIA) and an XIR with General Catalyst Partners.  Dr Gliklich is well known...